November 22, 2011

Gilead’s $11 Billion Gambit


Gilead Sciences Inc.'s agreement to pay nearly $11 billion to acquire tiny Pharmasset Inc. is a dramatic illustration of the market potential—and public-health challenges—involved in the battle against the hepatitis C virus… "Having a program where you don't have to take interferon…would be a big deal and would be a paradigm shift in the treatment of hepatitis C," said Stacey Rizza, an infectious-disease specialist at the Mayo Clinic in Rochester, Minn.

Wall Street Journal,  by Ron Winslow, 11/21/11

Tags: Business Relations, Infectious Diseases, Stacey Rizza

Please sign in or register to post a reply.
Contact Us · Privacy Policy